El invento se refiere a nuevos antagonistas 1-adrenoceptores de la fórmula I (gráfico), en donde: R1 es acetilamino, amino, ciano, trifluoroacetilamino, halo, hidro, hidroxilo, nitro, metilsulfonilamino, 2-propiniloxilo, un grupo elegido entre (C1-6) alquilo, (C3-6) cicloalquilo, (C3-6)-cicloalquil (C1-4) alquilo, (C1-6) alquiloxilo, (C3-6) cicloalquil-oxilo, (C3-6) cicloalquil (C1-4) alquiloxilo y (C1-4) alquiltio (cuyo grupo está opcionalmente sustituido adicionalmente por uno a tres tomos de halo) o un grupo elegido entre arilo, aril-(C1-4) alquilo, heteroarilo, heteroaril(C1-4)= alquilo, ariloxi, aril (C1-4)-alquiloxilo, heteroariloxilo y heteroaril (C1-4)-alquiloxilo (cuyo arilo y heteroarilo están opcionalmente sustituidos adicionalmente por uno a dos radicales elegidos independientemente entre halo y ciano); R2 es ciano, halo, hidro, hidroxilo, o un grupo elegido entre (C1-6) alquilo y (C1-6) alquiloxilo (cuyo grupo está opcionalmente sustituido adicionalmente por uno a tres tomos de halógeno); R3 y R4 son ambos hidro o metilo o juntos son etileno y R5 es un grupo elegido de las fórmulas (a), (b), (c) y (d) (gráfico), en donde X es C(O), CH2 o CH(Oh); Y es CH2 O CH(OH); Z es N o C(R), en donde R9 es hidro, (C1-6) alquilo o hidroxilo R6 es hidro, un grupo elegido entre (C1-6) alquilo, (C3-6) cicloalquilo, (C3-6) cicloalquil (C1-4) alquilo (cuyo grupo está opcionalmente sustituido adicionalmente por uno o tres tomos de halo) o un grupo elegido entre arrilo, heteroarilo, aril (C1-4) alquilo y heteroaril (C1-4) alquilo (cuyo arilo y heteroarilo están opcionalmente sustituidos adicionalmente por uno o tres radicales elegidos entre halo, ciano, (C1-6) alquiloxilo, (C1-6)-alquilo y arilo; R7 es (C1-6) alcanoilo, carbamoilo, ciano, di(C1-6)alquilamino, halo, hidro, hidroxilo, hidroximinometilo, (C1-6) alquil-sulfonilo (C1-4) alquiltio, un grupo elegido entre (C1-6) alquilo (C3-6) cicloalquilo, (C1-6) alquiloxilo y (C1-6) alquil-oxi (C1-4) alquilo (cuyo grupo está opcionalmente sustituido adicionlmente por uno a tres radicales elegidos entre halo, hidroxilo o (C1-6) alquiloxilo o un grupo elegido entre arilo, heteroarilo, aril(C1-4) alquilo y heteroaril (C1-4) alquilo cuyo arilo y heteroarilo están opcionalmente sustituidos adicionalmente por uno a tres radicales elegidos entre halo, ciano (C1-6) alquiloxilo, (C1-6)alquilo y arilo o R7 y R9 juntos son tetrametileno; y cada R8 es independientemente hidro, hidroxilo, metilo, etilo; y sus sales farmacéuticamente aceptables y N-óxidos.The invention relates to novel 1-adrenoceptor antagonists of formula I (graph), wherein: R1 is acetylamino, amino, cyano, trifluoroacetylamino, halo, hydro, hydroxyl, nitro, methylsulfonylamino, 2-propynyloxy, a group chosen from ( C1-6) alkyl, (C3-6) cycloalkyl, (C3-6) -cycloalkyl (C1-4) alkyl, (C1-6) alkyloxy, (C3-6) cycloalkyl-oxyl, (C3-6) cycloalkyl ( C1-4) alkyloxy and (C1-4) alkylthio (the group of which is optionally further substituted by one to three halo atoms) or a group chosen from aryl, aryl- (C1-4) alkyl, heteroaryl, heteroaryl (C1-4 ) = alkyl, aryloxy, (C1-4) aryl-alkyloxy, heteroaryloxy and heteroaryl (C1-4) -alkyloxy (which aryl and heteroaryl are optionally further substituted by one to two radicals independently chosen from halo and cyano); R2 is cyano, halo, hydro, hydroxyl, or a group chosen from (C1-6) alkyl and (C1-6) alkyloxy (the group of which is optionally further substituted by one to three halogen atoms); R3 and R4 are both hydro or methyl or together are ethylene and R5 is a group chosen from the formulas (a), (b), (c) and (d) (graph), where X is C (O), CH2 or CH (Oh); Y is CH2 O CH (OH); Z is N or C (R), where R9 is hydro, (C1-6) alkyl or hydroxyl R6 is hydro, a group chosen from (C1-6) alkyl, (C3-6) cycloalkyl, (C3-6) cycloalkyl (C1-4) alkyl (the group of which is optionally further substituted by one or three halo atoms) or a group chosen from aryl, heteroaryl, aryl (C1-4) alkyl and heteroaryl (C1-4) alkyl (whose aryl and Heteroaryl are optionally further substituted by one or three radicals chosen from halo, cyano, (C1-6) alkyloxy, (C1-6) -alkyl and aryl; R7 is (C1-6) alkanoyl, carbamoyl, cyano, di (C1- 6) alkylamino, halo, hydro, hydroxyl, hydroxyminomethyl, (C1-6) alkyl-sulfonyl (C1-4) alkylthio, a group chosen from (C1-6) alkyl (C3-6) cycloalkyl, (C1-6) alkyloxy and (C1-6) alkyl-oxy (C1-4) alkyl (the group of which is optionally further substituted by one to three radicals chosen from halo, hydroxyl or (C1-6) alkyloxy or a group chosen from aryl, heteroaryl, aryl ( C1-4) alkyl and heteroaryl (C1 -4) alkyl whose aryl and heteroaryl are optionally further substituted by one to three radicals chosen from halo, cyano (C1-6) alkyloxy, (C1-6) alkyl and aryl or R7 and R9 together are tetramethylene; and each R8 is independently hydro, hydroxyl, methyl, ethyl; and its pharmaceutically acceptable salts and N-oxides.